comparemela.com

Latest Breaking News On - Reiterated rating - Page 6 : comparemela.com

Stifel Nicolaus Reaffirms Hold Rating for Vestis (NYSE:VSTS)

Stifel Nicolaus reissued their hold rating on shares of Vestis (NYSE:VSTS – Free Report) in a research report released on Friday morning, MarketBeat.com reports. Several other equities research analysts have also recently issued reports on VSTS. Barclays lowered their target price on shares of Vestis from $19.00 to $10.00 and set an underweight rating on […]

United-states
Canada
James-phillip-holloman
Stifel-nicolaus
Kim-scott
Robertw-baird
Ci-investments-inc
Vestis-corporation
Income-strategies
Barclays
Parkside-financial-bank
Wealth-partners

DraftKings' (DKNG) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of DraftKings (NASDAQ:DKNG – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage currently has a $58.00 target price on the stock. A number of other equities analysts have also recently issued reports on the stock. JPMorgan […]

United-states
Stifel-nicolaus
Jason-robins
America-bofa
Draftkings-inc
Highlander-capital-management
Securities-exchange-commission
Needham-company
Montaga-associates-inc
Transcendent-capital-group
Morgan-stanley
Jpmorgan-chase-co

Rosenblatt Securities Reaffirms "Neutral" Rating for Apple (NASDAQ:AAPL)

Rosenblatt Securities reiterated their neutral rating on shares of Apple (NASDAQ:AAPL – Free Report) in a report released on Friday, Benzinga reports. Rosenblatt Securities currently has a $196.00 price objective on the iPhone maker’s stock, up from their prior price objective of $189.00. Other equities analysts also recently issued reports about the company. Piper Sandler […]

Arthurd-levinson
Luca-maestri
Citigroup
Minichmacgregor-wealth-management
Ppsv-asset-management-consultants-inc
Piper-sandler-companies
Buttonwood-financial-advisors-inc
Apple-inc
Arcus-capital-partners
Nasdaq
Edmonds-duncan-registered-investment-advisors
Rosenblatt-securities

Oppenheimer Reiterates "Market Perform" Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Oppenheimer reiterated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $19.00 target price on the biopharmaceutical company’s stock. ACAD has been the topic of a number of other research reports. JPMorgan Chase & Co. decreased their price […]

Canada
United-states
China
Robertw-baird
Brendan-teehan
Stephen-davis
Quest-partners
Pharmaceuticals-daily
Pharmaceuticals-trading-down
Royal-bank
Securities-exchange-commission
Legato-capital-management

XPEL (NASDAQ:XPEL) Receives Neutral Rating from B. Riley

B. Riley reiterated their neutral rating on shares of XPEL (NASDAQ:XPEL – Free Report) in a report released on Friday morning, MarketBeat.com reports. B. Riley currently has a $37.00 target price on the stock, down from their previous target price of $74.00. XPEL Stock Performance XPEL stock opened at $32.34 on Friday. The company has […]

Mendota
California
United-states
Los-angeles
Los-angeles-capital-management
Aristides-capital
Company-profile
Mendota-financial-group
Xpel-inc
Free-report
Get-free-report

vimarsana © 2020. All Rights Reserved.